Stock Comparison

CAPR vs JNJ

Capricor Therapeutics Inc vs Johnson & Johnson

The Verdict

CAPR takes this one.

Winner

CAPR

Capricor Therapeutics Inc

7.8

out of 10

Solid Pick

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Head-to-Head

$1.7B

Market Cap

$557.1B

-13.4

P/E Ratio

26.5

-181.7%

Profit Margin

21.8%

-59.3%

Return on Equity

26.3%

0.0

Debt-to-Equity

0.6

Aggressive

Overall Risk

Conservative

7.8

DVR Score

1.0

The Deep Dive

CAPR7.8/10

Capricor Therapeutics (CAPR) maintains its high-risk, high-reward profile, with its valuation hinging primarily on the upcoming FDA PDUFA date of August 22, 2026, for Deramiocel in Duchenne Muscular Dystrophy (DMD). The multi-billion dollar TAM and Deramiocel’s unique cell therapy mechanism offer substantial 10x growth potential if approved. Despite a strong cash position of $278.6 million providi...

Full CAPR Analysis

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.